Navigation Links
BioMS Medical to present at BIO CEO and Investor Conference
Date:2/5/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York.

    WHEN:     Monday February 9th at 2:45pm (Eastern Time)

    WHERE:    Waldorf-Astoria, New York City


    About BIO CEO & Investor Conference
    -----------------------------------
    This conference aims to bring together institutional investors, industry
analysts, and senior biotechnology executives in a neutral and collaborative
forum to examine investment opportunities and issues affecting the industry.
For more information visithttp://ceo.bio.org/opencms/ceo/2009/index.jsp.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that ma
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
2. BioMS Medical recognized at Scrip Awards 2008
3. BioMS Medical Announces Third Quarter 2008 Results
4. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
8. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
9. BioMS Medical to present at UBS Global Life Sciences Conference
10. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... ... hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting in Palm Springs, ... executive Research and Development team to discuss new clinical practice and research ideas. ...
(Date:7/6/2015)... Research and Markets ... the "Biotechnology for the Non-Biotechnologist" conference ... Non-Biotechnologist, ideal for non-Scientists and Scientists needing to ... of biotechnology. Ideal for Non-Scientists and ... techniques, and potential of biotechnology Why ...
(Date:7/5/2015)... ... 2015 , ... For many years, metal-on-quartz filters were the industry standard for ... a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu 3600-3700, these filters ... them for their SRM-2031 series going back for many years. Unfortunately, these standards remained ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is ... to 2020. The bioscience market is expected to grow at the highest CAGR of ... analysis equipment in the research labs and academic institutions for root cause analysis of ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... December 11 Olympus has further,cemented its position as ... signing an exclusive and immediate deal to distribute the ... the sole global,provider of ports for state-of-the-art laparoscopic operative ... Olympus is now the exclusive,distributor for the full range ...
... PPHM ) today announced that Thomas A. Waltz, M.D., ... Dr. Waltz had been a director of Peregrine since 2004 ... death, Dr. Waltz served on Peregrine,s Audit Committee, Compensation Committee and ... "The sudden loss of our business colleague and friend Tom Waltz ...
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) ... statistical endpoint in its multi-centre Phase 2 clinical ... in patients with various sarcomas that have metastasized ... of patients on study with significant, durable, clinically ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... ) can today be found all over Central Europe, Asia, ... in the Iberian Peninsula at the end of the Early ... an international research study, with Spanish participation, which has discovered ... of fossils found in the Cueva Victoria deposit in Cartagena ...
... of newly installed, hands-free faucets at The Johns Hopkins Hospital, ... hands and dispense preset amounts of water, shows they were ... common and hazardous bacteria in hospitals compared to old-style fixtures ... "Newer is not necessarily better when it comes to ...
... (SACRAMENTO, Calif.) UC Davis cancer researchers have found ... for surveillance with regular CT scans over lymph node ... findings, published online last week in the journal Cancer, ... cancers with surveillance when discussing treatment options with their ...
Cached Biology News:Green toad inhabited Iberian Peninsula 1 million years ago 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 3Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 4Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
... BMH 71-18 mutS and ES1301 mutS ... coli. Use of these strains prevents repair ... leading to high mutation efficiencies and making ... GeneEditor and Altered Sites II Mutagenesis Systems. ...
propidium iodide *1.0 mg/mL solution in water*...
Biology Products: